<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152889</url>
  </required_header>
  <id_info>
    <org_study_id>ZG IIIS</org_study_id>
    <nct_id>NCT04152889</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer</brief_title>
  <official_title>A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 Sequenced by Camrelizumab+S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Camrelizumab in Combination With Docetaxel +S-1
      Sequenced by Camrelizumab+S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer
      (PD-L1 + / MSI-H / EBV +/dMMR) . Secondary study objective: To observe and evaluate the
      overall survival and adverse events of Camrelizumab in Combination With Docetaxel +S-1
      Sequenced by Camrelizumab+S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer
      (PD-L1 + / MSI-H / EBV +/dMMR). To evaluate the safety ofCamrelizumab in Combination With
      Docetaxel +S-1 Sequenced by Camrelizumab+S-1 as Adjuvant Treatment Therapy in Stage III
      Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR). Objective: To explore the incidence of PD-L1 +
      / MSI-H / EBV + /dMMR in stage III gastric cancer. To explore the correlation of PD-L1 + /
      MSI-H / EBV + /dMMR in stage III gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>1YEARS</time_frame>
    <description>disease-free survival</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gastric Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>Camrelizumab+chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab, 200 mg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.</description>
    <arm_group_label>Camrelizumab+chemotherapy</arm_group_label>
    <other_name>SHR-1210</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>Tegafur-gimeracil-oteracil potassium: 80 - 120 mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.</description>
    <arm_group_label>Camrelizumab+chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel: 40 mg/m^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.</description>
    <arm_group_label>Camrelizumab+chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patients voluntarily joined the study and signed the informed consent;

          2. ≥ 18 years old, ≥ 80 years old, both male and female;

          3. Stage III gastric cancer confirmed by pathology,

          4. ECoG score: 0-1

          5. Detection of biomarkers in postoperative gastric cancer samples suggests that: PD-L1 +
             CPS ≥ 10% / MSI-H + / EBV+/dMMR

          6. No preoperative anti-tumor treatment for gastric cancer, including chemotherapy and
             local treatment

          7. During the study treatment period and within 3 months after the end of the study
             treatment period, a medically recognized contraceptive measure (such as IUD,
             contraceptive pill or condom) should be used for the female patients of non-surgical
             sterilization or childbearing age; the serum or urine HCG test of the female patients
             of non-surgical sterilization must be negative within 72 hours before the study group;
             and the hCG test must be non lactation; for the male patients Sex, should be surgical
             sterilization, or agree to use appropriate methods of contraception during the trial
             and within 3 months after the last administration of the test drug.

          8. The baseline blood routine and biochemical indexes of the selected patients should
             meet the following standards:

        A. hemoglobin ≥ 90g / L

        B. absolute neutrophil count ≥ 1.5 × 10 ^ 9 / L

        C. platelet count ≥ 100 × 10 ^ 9 / L

        D. ASTor ALT ≤ 2.5 ULN

        E. Alkaline phosphatase (ALP)≤ 2.5×ULN

        TSH ≤ 1 ULN (if abnormal, T3 and T4 levels should be examined at the same time, if T3 and
        T4 levels are normal, they can be included in the group);

        Exclusion Criteria:

          1. Pregnant or lactating women;

          2. Women of childbearing age were positive in the baseline pregnancy test;

          3. Distant metastasis was diagnosed by CT /MR/ EUS.

          4. Received previous anti-tumor treatment, including chemotherapy, radiotherapy or
             immunotherapy;

          5. Have other malignant tumors in the past 5 years (except basal cell or squamous cell
             carcinoma, superficial bladder cancer, cervical cancer in situ or breast cancer);

          6. Uncontrollable pleural effusion, pericardial effusion or ascites;

          7. Severe cardiovascular diseases such as symptomatic coronary heart disease, congestive
             heart failure ≥ level II, uncontrolled arrhythmia and myocardial infarction within 12
             months before admission;

          8. With gastroduodenal obstruction/bleeding, digestive dysfunction or malabsorption
             syndrome

          9. Complicated with severe uncontrolled concurrent infection or other serious
             uncontrolled concomitant diseases, moderate or severe renal injury;

         10. Allergic reaction to the drugs used in this study;

         11. Steroid or other systemic immunosuppressive therapy was used 14 days before admission;

         12. Patients who received study drug treatment within 4 weeks before enrollment
             (participate in other clinical trials).

         13. Active autoimmune diseases (including but not limited to: uveitis, enteritis,
             hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, hypothyroidism and
             asthma requiring bronchodilator treatment). Subjects with hypothyroidism requiring
             only hormone replacement therapy and skin diseases without systemic treatment (such as
             vitiligo, psoriasis or alopecia) can be selected.

         14. History of primary immunodeficiency.

         15. Immunosuppressive drugs were used within 4 weeks prior to the first dose of study
             treatment, excluding local or physiological doses of systemic glucocorticoids (i.e. no
             more than 10mg / day of prednisone or other glucocorticoids of equivalent dose) by
             nasal spray, inhalation or other routes, or hormones used to prevent allergy of
             contrast agents.

         16. Receive live attenuated vaccine within 4 weeks before the first dose of study
             treatment or during the study period.

         17. Active tuberculosis is known.

         18. We have known the history of allogeneic organ transplantation and allogeneic
             hematopoietic stem cell transplantation.

         19. HIV antibody positive, active hepatitis B or C (hepatitis B: HBsAg positive and HBV
             DNA ≥ 10 ⁴ copies / ml; hepatitis C: HCV antibody and HCV-RNA positive, requiring
             antiviral treatment at the same time);.

         20. Other factors that may affect the safety or test compliance of the subjects according
             to the judgment of the researchers. For example, serious diseases (including mental
             diseases) requiring combined treatment, serious laboratory abnormalities, or other
             family or social factors, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Zhao</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital, Shanghai JiaoTong University, School of Medicine Shanghai, Shanghai, China, 200127</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gang Zhao</last_name>
    <phone>0086-021-68383731</phone>
    <email>zhaogang74313@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Zhao</last_name>
      <phone>0086-021-68383731</phone>
      <email>zhaogang74313@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>zhaogang</investigator_full_name>
    <investigator_title>Deputy director of gastrointestinal surgery administration</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

